Cancer Immunotherapy 102 (2023 AMW)
2023 AAO-HNSF Annual Meeting & OTO Experience
This is the second part of the popular course, previously named Immunotherapy for Cancer: What the Otolaryngologist needs to Know. In recent years immunotherapy has shown promise as a new therapeutic pathway for the treatment of head and neck cancer. The second part of this course will focus on emerging biomarkers in oncology, ongoing clinical trials and exciting future directions for the field. Understanding the current state and future directions of immunotherapy is valuable for counseling patients. This panel, geared toward general otolaryngologist, head and neck surgeons and trainees, will provide an in-depth review of biomarkers, ongoing clinical trials, and potential future agents.
Credits
CME:1.0, MOC:1.0